Amprenavir ( DrugBank: Amprenavir )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
265	脂肪萎縮症	2

265. 脂肪萎縮症

---

臨床試験数 : 116 /  薬物数 : 170 - (DrugBank : 61) / 標的遺伝子数 : 26 - 標的パスウェイ数 : 97

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00192660 (ClinicalTrials.gov)	February 2003	12/9/2005	HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)	Analysis of Lipodystrophy in HIV-Infected Individuals A Prospective, Non-randomised, 48 Week Study of the Effect of PI Containing and Non-PI Containing Antiretroviral Regimens on the Expression of Adipocyte Specific Genes, Protein Levels and Cellular Structure in HIV-infected Individuals, Naive to Therapy, Who Are Starting Therapy for the First Time	HIV-Associated Lipodystrophy Syndrome;Cardiovascular Disease	Drug: Lamivudine;Drug: Stavudine;Drug: Didanosine;Drug: Zidovudine;Drug: Tenofovir;Drug: Abacavir;Drug: Efavirenz (EFV);Drug: Nevirapine;Drug: Indinavir;Drug: Saquinavir;Drug: Amprenavir;Drug: Ritonavir;Drug: Nelfinavir;Drug: Tipranavir;Drug: enfuvirtide (T20)	Kirby Institute	St Vincent's Hospital, Sydney;National Heart, Lung, and Blood Institute (NHLBI)	Completed	18 Years	N/A	Both	80	Phase 4	Australia
2	NCT00002417 (ClinicalTrials.gov)	March 1998	2/11/1999	A Study of Amprenavir in Patients With Protease Inhibitor-Related Complications	An Open-Label Study to Evaluate the Safety and Tolerance of Amprenavir (141W94) Combination Therapy in Protease Inhibitor Experienced Subjects Who Are Intolerant (Hyperlipidemia With or Without Lipodystrophy) But Not Failing Their Current Protease Inhibitor Therapy	HIV Infections	Drug: Amprenavir	Glaxo Wellcome	NULL	Completed	13 Years	N/A	Both		N/A	United States